Brought to you by 
AZ pays $240mm up front for mRNA collaboration with Moderna
10 Aug 2016
Executive Summary
Marking the largest up-front for a non-marketed product so far this year, AstraZeneca PLC has paid Moderna Therapeutics Inc. (messenger RNA therapeutic development for various diseases) $240mm for options to develop and sell up to 40 new cardiometabolic, renal, and cancer compounds based on Moderna’s messenger RNA Therapeutics technology.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com